TMP001 in relapsing-remitting multiple sclerosis: a multicentre open, baseline-controlled phase IIa clinical trial TMP001
Latest Information Update: 27 Nov 2018
At a glance
- Drugs Tarenflurbil (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 02 May 2018 Status changed from recruiting to completed.
- 22 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 22 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.